Biotech Values

[jbog]

While Wedbush is declaring that Momenta is undervalued at this point it seems obvious that the street has put Momenta in the exact position of any major pharma who's about to lose one of their main products to generic competition. PFE today is priced at about 7X forward earnings, mainly because of the upcoming Lipitor expiration.

It seems that unless the FDA outright rejects Teva and Amphastar's Enox application (very unlikely), Momenta will not receive the proper credit.

It's now all up to the other events to carry this stock forward. It seems that Copax is just as valuable to Mnta's stock price as Enox is at this point. Any Copax setback would hurt.